The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
ALL FUNDED GRANTS (1280)
Biomarker Development, 2015
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson's disease (PD) pathology. Such an agent will help (i) diagnose PD earlier, (ii) track pathology over time and (iii) monitor the efficacy of therapeutics reducing alpha-synuclein aggregates. The AC Immune team identified promising compounds that will be refined to target such a...
Access to Data and Biospecimens, 2015
The dysfunction of the systems responsible for the clearance of the protein alpha-synuclein plays a major role in Parkinson's disease (PD). The lysosome is an important sub-cellular compartment for alpha-synuclein disposal. Among the many lysosomal enzymes responsible for this degradation, major attention has been given to glucocerebrosidase (GCase). Several repo...
Rapid Response Innovation Awards, 2014
Although the causes of Parkinson's disease (PD) are yet unknown, the overall health of the body likely plays a major role in disease initiation and progression. However, maintenance and/or restoration of normal systemic activity have been largely overlooked by current pharmaceutical treatments — an approach that has led to a scarcity of effective disease-modifying ...
Access to Data and Biospecimens, 2014
We have discovered a long, non-coding RNA (RNA that does not encode a protein) that shows a five-fold decrease within the brains of people with Parkinson's disease (PD) compared to similarly aged healthy individuals. This RNA is also found within human blood, and we hope that its level in blood could serve as a peripheral PD biomarker. Validation of a biological marker of PD...
Researchers: Antony A. Cooper, PhD
Research Grant, 2014
Mutations in GBA1, the gene encoding the protein glucocerebrosidase, represent a common genetic risk factor for developing Parkinson disease (PD). PD patients with and without GBA1 mutations exhibit lower levels of glucocerebrosidase in the central nervous system (CNS), suggesting a strong correlation between low glucocerebrosidase activity and the development of t...
Researchers: Sergio Pablo Sardi, PharmD, PhD